ESMO 2022 | CD8 T-cell receptor signatures of response to checkpoint immunotherapy

Benjamin Fairfax, BM BCh, MRCP, PhD, University of Oxford, Oxford, UK, discusses the findings of an investigation that aimed to characterize CD8 T-cell receptor signatures of response to immune checkpoint inhibitors. Deep sequencing of the T-cell receptor of CD8+ T-cells isolated from peripheral blood of patients receiving checkpoint inhibitor therapy revealed signatures that expand with immunotherapy and are associated with long-term clinical responses. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.